文献速递炎症性肠病

妊娠期使用维得利珠单抗的出生结局:来自维得利珠单抗妊娠暴露登记研究的结果

Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry.
PubMed 文献 · Am J Gastroenterol · 2025-06-11

该前瞻性观察性妊娠暴露登记研究纳入275名美国或加拿大孕妇,分为维得利珠单抗暴露组(N=99)、疾病匹配但未暴露于维得利珠单抗而使用其他生物制剂组(N=76)及无慢性健康问题未暴露组(N=100),随访至产后1年。维得利珠单抗暴露组与疾病匹配组相比,重大出生缺陷、自然流产及早产风险均无统计学显著升高。

要点

  • 维得利珠单抗暴露组重大出生缺陷7/94(7.4%)vs 疾病匹配组4/71(5.6%),校正风险比1.07(95%CI 0.33, 3.52)。
  • 维得利珠单抗暴露组自然流产风险与疾病匹配组相比无统计学显著升高(校正风险比1.01,95%CI 0.17, 5.89)。
  • 维得利珠单抗暴露组早产风险略高但未达统计学显著(校正风险比1.58,95%CI 0.65, 3.82)。

核心结论

  • 维得利珠单抗暴露未使任何其他研究结局的风险显著增加。
  • 这些数据为支持维得利珠单抗妊娠期安全性增添了令人安心的证据。

研究设计与样本

  • 2015年至2022年间,致畸信息专家组织在美国或加拿大开展前瞻性观察性妊娠登记研究,纳入275名孕妇。
  • 孕妇分为三组:维得利珠单抗暴露组(N=99)、疾病匹配但未暴露于维得利珠单抗而使用其他生物制剂组(N=76)、无慢性健康问题未暴露组(N=100)。
  • 通过母亲访谈、问卷、病历摘录及部分婴儿体格检查随访至产后1年。

主要发现

  • 整个登记研究中,275例妊娠中17例(6.2%)失访。
  • 在至少分娩1名活产儿的妊娠中,维得利珠单抗暴露组7/94(7.4%) vs 疾病匹配组4/71(5.6%)发生重大出生缺陷,校正风险比1.07(95%CI 0.33, 3.52)。
  • 与疾病匹配组相比,维得利珠单抗暴露组发生自然流产的可能性无统计学显著升高(校正风险比1.01,95%CI 0.17, 5.89)。
  • 维得利珠单抗暴露组早产可能性略高但未达统计学显著(校正风险比1.58,95%CI 0.65, 3.82)。

关键数值与推荐

  • 维得利珠单抗暴露组重大出生缺陷7/94(7.4%) vs 疾病匹配组4/71(5.6%),校正风险比1.07(95%CI 0.33, 3.52)。
  • 维得利珠单抗暴露组自然流产校正风险比1.01(95%CI 0.17, 5.89),与疾病匹配组相比无统计学显著差异。
  • 维得利珠单抗暴露组早产校正风险比1.58(95%CI 0.65, 3.82),与疾病匹配组相比无统计学显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 整个登记研究中275例妊娠有17例(6.2%)失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There are limited data on the safety of vedolizumab in pregnancy for the treatment of Crohn's disease or ulcerative colitis. Between 2015 and 2022, the Organization of Teratology Information Specialists conducted a prospective, observational pregnancy registry study with 275 pregnant women residing in the United States or Canada. METHODS: Women were enrolled in 1 of 3 cohorts: vedolizumab-exposed (N = 99); disease-matched unexposed to vedolizumab, but treated with another biologic in pregnancy (N = 76); or unexposed with no chronic health conditions (N = 100). Women and their infants were followed up to 1 year postpartum with maternal interviews, questionnaires, medical records abstraction, and a subset of infants who received a physical examination. Study outcomes were major structural birth defects, minor birth defects, pregnancy loss, preterm delivery, prenatal and postnatal growth deficiency, serious or opportunistic infections, malignancies, and developmental milestones. RESULTS: In the overall registry, 17 of 275 pregnancies (6.2%) were lost to follow-up. Among pregnancies ending in at least 1 live born infant, 7 of 94 (7.4%) in the vedolizumab-exposed cohort compared with 4 of 71 (5.6%) in the disease-matched cohort had a major birth defect (adjusted risk ratio 1.07, 95% confidence interval [CI] 0.33, 3.52). Compared with the disease-matched cohort, women in the vedolizumab-exposed group were not statistically significantly more likely to experience spontaneous abortion (adjusted hazard ratio 1.01, 95% CI 0.17, 5.89). Women in the vedolizumab-exposed group were slightly but not significantly more likely to deliver preterm (adjusted hazard ratio 1.58, 95% CI 0.65, 3.82). CONCLUSIONS: No significant increased risks were noted with vedolizumab exposure for any of the other study outcomes. These data add reassuring evidence in support of the safety of vedolizumab in pregnancy.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Chambers CD, Johnson DL, Luo Y, et al. Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry. Am J Gastroenterol. 2025. PMID: 40498121. doi:10.14309/ajg.0000000000003593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。